Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

about

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

Item

http://www.wikidata.org/entity/Q48234735

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@en

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@nl

type

Item

label

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@en

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@nl

prefLabel

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@en

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

@nl

P1476

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension

@en

P2093

Steven G Chrysant

http://www.w3.org/2001/XMLSchema#string

P2860

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

From ARB to ARNI in Cardiovascular Control

Angiotensin-neprilysin inhibition versus enalapril in heart failure

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Clinical experience with angiotensin receptor blockers with particular reference to valsartan.

Natriuretic peptides and therapeutic applications.

The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects

P304

351-355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCH.13169

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Steven G Chrysant

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29338112

http://www.w3.org/2001/XMLSchema#string